Pharmaceutical Technology on MSN9h
FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases
Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...
Renal & Urology News13d
Non-Invasive Imaging of IgA Nephropathy Severity May Be Feasible
Fibroblast activating protein inhibitor (FAPI) PET/CT imaging may be a non-invasive modality to monitor IgA nephropathy (IgAN) progression, preliminary study results suggest.
Clinical Trials Arena on MSN21d
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR
In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.